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The European Association for Cardiovascular Imaging (EACVI) has outlined the rationale for setting appropriate use criteria (AUC) in
cardiovascular (CV) imaging. Transthoracic echocardiography (TTE) is the most common imaging modality in CV disease and is a cen-
tral tool in diagnosis, follow-up, management planning and intervention. The purpose of AUC is to inform referrers, both to avoid
under-use, which may result in incomplete or incorrect diagnosis and treatment, and also over-use, which may delay correct diagnosis,
lead to ‘treatment cascade’, and wastes resources. The first step in defining AUC for TTE in the adult has been for a panel of experts
in echocardiography to review the evidence, guidelines, recommendations, and position papers from the European Society of
Cardiology, EACVI and other specialist societies, and current state-of-the-art clinical practice. The attached document summarizes this
work, which will be used to under-pin the development of AUC.
...................................................................................................................................................................................................
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Introduction
Transthoracic echocardiography (TTE) is a central tool in the diagnosis
and management of cardiovascular (CV) disease that has contributed
to a halving in the frequency of major diagnostic errors over the last
20 years.1 Although use of TTE appears to grow inexorably and exces-
sive use is discouraged given the increasing costs of health-care, there
is evidence that it continues to be under-utilized in critical CV condi-
tions.2 This literature review aims to inform the development of
European Appropriate Use Criteria (AUC) for TTE in the adult.
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emergency setting
This section relates to the use of TTE in serious, unexpected situ-
ations that are potentially life threatening and may require immediate
action (Table 1).
Cardiac arrest
A number of causes of cardiac arrest may be identified promptly on
echocardiography without interference with the quality of resuscita-
tion, including tamponade, massive pulmonary embolism, tension
pneumothorax, hypovolaemia, complications of acute MI, and severe
systolic dysfunction.3 The use of TTE in these situations provides add-
itional information to clinical examination by measurement of ven-
tricular size and function, including wall motion, pericardial effusion,
estimation of intracardiac and intrapulmonary pressure and wall mo-
tion without compromise to the patient. Immediate echocardiog-
raphy is mandatory in patients with haemodynamic instability,
particularly in those patients suspected of having acute, life-
threatening structural or functional cardiovascular abnormalities such
as acute valvar regurgitation, pericardial tamponade, and aortic
dissection.
Shortness of breath (SOB)
Severe, persistent, abrupt onset or rapidly progressive SOB due to a
range of causes is a common reason for emergency presentation.
TTE is the imaging modality of choice and provides incremental diag-
nostic information with respect to the most common CV causes,
most frequently acute heart failure with or without preserved EF
(HF), valvular heart disease (VHD), pulmonary arterial disease, cor-
onary artery disease (CAD), cardiomyopathy (CM), and pericardial
disease.4 In addition, TTE adds incremental information to clinical and
radiological examination in patients with chronic lung disease who
have suffered an unexplained, sudden change in clinical status. In
these patients, early TTE may help to separate patients with cardio-
genic shock, in which case urgent pharmacological or mechanical cir-
culatory support should be instituted, from those with respiratory
failure, in which case urgent non-invasive positive pressure ventilation
or mechanical ventilatory support may be required. Early TTE en-
ables prompt recognition of left vs. right-sided pressure and volume
overload, thereby directing both diagnosis and management.
Acute heart failure
HF is the most frequent CV cause of hospitalization with SOB. In all
patients with acute onset of symptoms and suspected HF, early TTE
is mandated.5 TTE provides immediate information on chamber vol-
umes, ventricular systolic and diastolic function, filling pressure, wall
thickness, valve function and presence of pericardial effusion (PEff),
while contributing to information on aetiology. Although TTE is fre-
quently used in these situations, no large-scale randomized studies
comparing different diagnostic strategies with and without TTE exist.
There is growing evidence to support the use of pocket size echo
devices (PSED) to supplement physical examination and provide
more rapid, accurate clinical diagnosis in emergency situations.6 A
further alternative, although a comprehensive TTE provides more in-
formation, may be to perform focused TTE in critically-ill patients in
whom predominantly rapid, qualitative, gross assessment of cardiac
morphology, and function may be sufficient to guide treatment.7 Lung
ultrasound may be performed with both PSED and standard echocar-
diography equipment and is helpful in distinguishing the cause of
acute breathlessness, including pneumothorax, interstitial oedema,
and pleural effusions.8
Pulmonary embolism (PE)
TTE may rarely identify main and proximal PE, although this finding is
associated with increased mortality.9 Numerous echocardiographic
....................................................................................................................................................................................................................
Table 1 Clinical scenarios for echocardiography in the emergency setting
Scenario Conditions identified on TTE Focus of assessment
Cardiac arrest Tamponade, massive pulmonary embolism, tension pneumothorax, hypo-
volaemia, complications of acute MI and severe systolic dysfunction.
LV size and function, RV size and
function, proximal aorta,
pericardium
Shortness of breath Acute heart failure with or without preserved EF (HF), valvular heart dis-
ease (VHD), pulmonary arterial disease, coronary artery disease (CAD),
cardiomyopathy (CM) and pericardial disease
LV size, wall thickness and function,
RV size and function, pericardium
Chest pain Acute coronary syndrome, acute aortic syndromes, pulmonary embolism,
and pericardial disease
LV size and function, RV size and
function, aorta, pericardium
Cardiac trauma Direct effects of trauma and complications, transient regional wall motion
abnormalities and ventricular dilatation, cardiac rupture, valve lesions,
aortic dehiscence, pericardial effusion.
RV size and function, right heart
valves, proximal aorta,
pericardium
Syncope and palpitations Structural heart disease leading to haemodynamic instability and arrhyth-
mia, including acquired and congenital heart disease
LV size, wall thickness and function,
RV size and function, valves
Cardiac emergency
identified by other
investigation
Biomarker elevation and major adverse radiological finding LV size, wall thickness and function,
RV size and function, pericardium,
aorta
1192 R.P. Steeds et al.
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criteria for the diagnosis of PE have been identified which mostly rely
on secondary consequences of pressure overload on the right ven-
tricle, in which situation TTE has higher specificity.10 Although the
negative predictive value for PE overall is only 40–50%, TTE has a
role in promoting the diagnosis, for example with McConnell’s sign,
excluding differential diagnoses and in defining management. If clinical
suspicion remains after TTE, further imaging using alternate modal-
ities is required to confirm or refute the diagnosis of PE.11 Routine
TTE is not mandatory in the emergency setting in all cases but should
be performed in the non-urgent setting with a view to assessment of
complications.
While TTE has a limited role in diagnosis, in the emergency setting
in normotensive patients, tricuspid annular plane systolic excursion
below 15 mm carries adverse prognostic significance.12 In normoten-
sive patients with RV dysfunction on TTE, the benefits of rescue
reperfusion therapy appear to be limited to the avoidance of haemo-
dynamic compromise but at greater bleeding risk.13 In acute PE with
haemodynamic collapse, rescue reperfusion therapy may be indicated
without TTE.
Acute pulmonary disease
TTE may be used to diagnose a large pleural effusion or pneumo-
thorax, and to differentiate interstitial pulmonary oedema from pneu-
monia by the identification of linear artefacts called ‘lung comets’.14
The acoustic windows used and views required are not however
standard, and additional training may be required for this use.
Acute valvular heart disease
A murmur in a patient with acute cardiorespiratory compromise is
an indication for urgent TEE. Echocardiography detects abnormalities
of valve morphology and function, aetiology including IE, and haemo-
dynamic effects on chamber size and function. In emergency admis-
sions, VHD is likely to be severe and to affect the left-sided valves,
including flail MV and AV leaflets, prosthetic valve dehiscence, and
valve perforation in infective endocarditis.4
Chest pain
Identifying the aetiology of acute chest pain is often challenging and
requires careful history and examination, with the first step a 12-lead
electrocardiogram (ECG) if acute coronary syndrome is suspected.
When the history, ECG and biomarker findings are inconclusive, TTE
is then the most important imaging modality in the emergency setting,
not only because it can demonstrate transient wall motion abnormal-
ities during ischaemia and tako-tsubo but also because it may highlight
differential diagnoses including aortic dissection, PE, and pericardial
disease.15 TTE has a limited role in the diagnosis of acute myocarditis,
although the identification of PEff due to acute pericarditis presenting
with haemodynamic compromise is important.16
Acute coronary syndrome (ACS)
In those patients with a history and examination suggestive of ACS,
current guidelines recommend immediate angiography following 12-
lead ECG in those with ST-segment elevation MI.17 In those cases
when history, clinical risk score, and ECG fail to diagnose an ACS,
both myocardial contrast for perfusion and strain TTE may improve
diagnostic accuracy before serum biomarker results become available
dependent on local expertise.18 While the sensitivity of 2D-TTE wall
motion analysis for detecting an acute coronary occlusion in ACS is
only 71% in the modern biomarker era, this is substantially improved
with the addition of regional strain analysis to 90%.19 LV opacification
contrast should be used where image quality is sub-optimal and two
or more myocardial segments cannot be adequately visualized. In
addition, focused TTE should be available in the emergency room
and chest pain unit as it can be helpful to detect alternative patholo-
gies, such as proximal aortic dissection involving the coronary ostia,
without delaying revascularization.
Acute aortic syndromes
This term refers to the spectrum of aortic pathologies, comprising
aortic dissection, intramural haematoma, penetrating aortic ulcer,
and aortic aneurysm rupture. Prompt and accurate diagnosis of these
conditions is paramount due to their potentially lethal nature. Non-
invasive imaging techniques that play a core role include computed
tomography (CT), transesophageal echocardiography (TEE), mag-
netic resonance imaging (CMR) and TTE. The sensitivity of TTE has
improved such that it can be considered as the first-line imaging mo-
dality in the emergency room but, if negative, further imaging should
be performed.20 For any test performed under these circumstances,
expert interpretation is required to minimize risk of false positive and
false negative results, which may be a particular problem in this clin-
ical scenario.
Chest trauma
TTE should be used to assess the consequences of penetrating car-
diac trauma, although blunt cardiac contusion is more common. The
latter may cause a spectrum of pathology from transient regional wall
motion abnormalities to cardiac rupture, valve lesions (frequently tri-
cuspid), and aortic dehiscence. Echocardiography has high sensitivity
for detection of the complications of contusion, including intracardiac
shunts or thrombosis, PEff or tamponade, and ventricular
dilatation.21
Syncope or palpitations
There is a broad overlap in the clinical presentations of patients with
syncope in the emergency room that may potentially be due to ven-
tricular and supraventricular arrhythmias, as well as to other non-
arrhythmic causes such as hypovolaemia, pericardial tamponade, dy-
namic LV outflow tract obstruction in HCM and severe VHD. The
management and prognosis of each patient depends both on their
hemodynamic status on arrival and on severity of underlying CV dis-
ease. TTE is the first line imaging modality for diagnosis of underlying
myocardial, valvular and congenital disorders in highly symptomatic
patients with high-grade atrio-ventricular block, ventricular and
supraventricular arrhythmia and in complicated new-onset atrial fib-
rillation. The aims of imaging are not only diagnosis but also progno-
sis, guidance of therapy and monitoring.4 A normal TTE in this setting
is an important finding that helps to direct the clinician in diagnosis
and management. Presentation with palpitations may require the
same diagnostic and prognostic assessment as for syncope, although
urgency of imaging depends on haemodynamic compromise.
A report of literature and current practice review 1193
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Cardiac emergency suspected following
other investigation
This section refers to the use of TTE following another investigation
that has highlighted a serious, unexpected, potentially life-threatening
condition that may require immediate action. Most commonly the in-
vestigations include elevated cardiac biomarkers and abnormal radio-
logical findings.
Elevated troponin
Cardiac troponin testing is essential in the assessment of acute chest
pain. The role of TTE in those with suspected ACS has been dis-
cussed but particularly with high sensitivity assays, circulating tropo-
nin can be detected within 2–3 hrs in many other conditions,
including heart failure, aortic valve disease, acute aortic syndromes,
hypertrophic and restrictive cardiomyopathies, Tako-tsubo syn-
drome, endocarditis, and myocarditis. Dependent on clinical circum-
stances, early TTE may be important to direct treatment in these
circumstances, particularly in patients with shock, when troponin
may be elevated in critical illness due to non-cardiac causes including
sepsis, acute renal failure and burns. In these cases, TTE has an im-
portant role not only in excluding a cardiac component to hemo-
dynamic compromise but also in monitoring filling pressure,
response to volume-loading and pharmacotherapy.22
Elevated natriuretic peptides
Natriuretic peptides as markers of myocardial stretch are typically
elevated when heart chambers dilate as in HF, especially acutely, but
also in acute cardiomyopathies, severe VHD and arrhythmias.23
Natriuretic peptides may be elevated in non-primary cardiac illnesses,
including critical sepsis, severe anemia, stroke and pulmonary disease,
including PH.24 TTE may provide important additional diagnostic and
prognostic information in the critically ill patient.
Radiological abnormality
While a standard chest-X-ray is not an accurate method for diagnosis
of cardiomegaly or thoracic aortic dilatation, such a finding in the
emergency room in a patient with relevant symptoms, signs or past
medical history mandates early TTE.
Assessment of the patient prior to non-
cardiac emergency surgery
Prior to emergency non-cardiac surgery, the utility of TTE is unclear
due to the need for urgent intervention. Although there is a lack of
data, expert consensus suggests that TTE does not change the course
and outcomes of an urgent intervention, such as those for ruptured
abdominal aortic aneurysm, major trauma or perforated viscus,
whether or not the patient has a history of CV disease.25
Echocardiography in the non-
urgent, first assessment of the
patient
This section relates to the first use of TTE in patients hospitalized (in-
patient) or investigated as out-patients (Table 2). TTE will usually
follow the same protocol in either setting and there may be no differ-
ence in the indication for examination in many cases. This section
outlines evidence relating to the first use of TTE.
Shortness of breath
SOB is a common symptom affecting up to half of all acute hospital
admissions and a quarter of ambulatory patients and it may be the pri-
mary manifestation of CV disease, lung disease, anaemia, obesity, de-
conditioning and a host of other causes. In any setting, clinical history
and examination remain the first step in evaluation, although TTE
may improve accuracy in diagnosis and provide incremental
information.26
Acute and chronic heart failure
In all patients with suspected heart failure, early TTE is mandated.
The aims of TTE are to confirm or exclude the diagnosis, quantify
chamber volumes, systolic and LV diastolic function, wall thickness
and to identify the aetiology of heart failure. TTE provides an initial
diagnosis and treatment plan in the majority of patients; other imaging
may only be required if the diagnosis remains unclear.5 It is the pri-
mary imaging modality to identify HF with preserved, mid range or
reduced EF in those with breathlessness. TTE is also mandated in pa-
tients with known HF presenting with acute exacerbation, for identifi-
cation of a precipitating factor for deterioration.
Valvular heart disease (VHD)
SOB is the leading symptom of mitral valve disease, and is a common
presentation for a patient with VHD of any type. In patients present-
ing with SOB and suspected VHD based on history and/or examin-
ation, TTE is the primary imaging modality for diagnosis, assessment
of severity and of hemodynamic consequences.27
Cardiomyopathy (CM)
SOB may be a presenting symptom in CM of all types and TTE is a
fundamental step in diagnosis and classification of type, specifically
hypertrophic, dilated, arrhythmogenic, restrictive and unclassified
cardiomyopathies.28 It is also recognized that TTE should form the
first step in differentiating the heart of the athlete from serious car-
diovascular disease that may share morphological features.29
Hypertrophic cardiomyopathy (HCM)
TTE is the primary imaging modality in patients with HCM, providing
information on diagnosis, anatomy (LV hypertrophy, mitral valve ap-
paratus, intraventricular and LV outflow tract obstruction), ventricu-
lar systolic and diastolic function, mitral regurgitation, ischaemia,
staging and risk stratification. Supplementary manoeuvres, including
Valsalva and ergometric testing, may be necessary to identify signifi-
cant LVOT obstruction. TTE is an important tool to separate HCM
from phenocopies.30
Dilated cardiomyopathy (DCM)
DCM is defined by the presence of LV dilatation and LV systolic dys-
function in the absence of abnormal loading conditions (hyperten-
sion, valve disease) or coronary artery disease sufficient to cause
global systolic impairment. TTE is the primary imaging modality in
1194 R.P. Steeds et al.
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DCM, providing information on diagnosis, severity of ventricular dys-
function, staging and risk stratification.
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ARVC is characterized histologically by progressive replacement of
RV myocardium with adipose and fibrous tissue, frequently leading to
functional and morphological abnormalities that may be diagnosed
on TTE.31 Detection of RV dilatation and RV dysfunction in associ-
ation with regional hypokinesis represent major and minor diagnostic
imaging criteria, while it is also important to ensure there is a low like-
lihood of pulmonary hypertension. TTE is the primary imaging modal-
ity, although ARVC may be present in the absence of imaging criteria
of any type.
Restrictive cardiomyopathies (RCM)
RCMs are defined by the presence of restrictive ventricular physi-
ology with normal or reduced diastolic volumes (of one or both ven-
tricles), normal or reduced systolic volumes, and normal ventricular
wall thickness.28 These may be familial, including haemochromatosis,
Anderson-Fabry disease and glycogen storage disease, or non-
familial, including AL and wild-type TTR amyloid, endomyocardial fi-
brosis and carcinoid heart disease. TTE is not only the main diagnostic
imaging modality for RCM but is also useful for risk stratification.32
Lung disease
Two categories of patients with SOB and lung disease have been
defined: (a) those presenting for the first time; (b) those presenting
with an established diagnosis that may cause SOB but which has
deteriorated for no apparent reason.33 The role of TTE in patients
with primary lung disease presenting for the first time is not clear, ex-
cept in those with suspected PE or PH. In those with established lung
disease that may cause SOB but with unexplained deterioration, for
example in chronic obstructive pulmonary disease and sleep apnoea
syndrome, careful CV evaluation and TTE is necessary in order to de-
tect complicating factors such as HF.34
Pulmonary vascular disease
CT, ventilation-perfusion imaging and pulmonary angiography are the
imaging modalities of choice in the diagnosis of the non-urgent pa-
tient with suspected PE. TTE has a role during hospitalization as it
identifies those at risk of acute deterioration and determines progno-
sis.35 Furthermore, persistence of RV dysfunction on TTE at hospital
discharge is a marker for recurrence of PE.36
Pulmonary hypertension (PH)
The diagnosis of PH requires a high index of suspicion, as symptoms
and clinical signs are frequently non-specific and often relate to onset
of RV dysfunction. Doppler echocardiography is used to estimate the
pulmonary pressure from the maximal velocity of the tricuspid regur-
gitant jet (TR Vmax >2.8 m/sec), combined with additional variables
including relative RV to LV size, RV/LV eccentricity index, RA area-
> 18 cm2, RV outflow tract acceleration time (<105 ms), pulmonary
regurgitant velocity (>2.2 m/s), inferior vena cava dimensions and the
pulmonary artery diameter > 25 mm.37 Assessment of RV size and
function by TTE can be complicated by the need to use multiple
acoustic windows and is less accurate than CMR in this respect. In
....................................................................................................................................................................................................................
Table 2 Clinical scenarios for echocardiography in the non-urgent, first assessment of the patient
Scenario Conditions identified on TTE Focus of assessment
Shortness of breath Acute and chronic HF, VHD, cardiomyopathy, pericar-
dial disease, pulmonary vascular disease, pulmonary
hypertension
LV size, wall thickness and function, RV size and func-
tion, valve function, pericardium
Chest pain Acute coronary syndrome, chronic stable angina, VHD,
acute aortic syndromes, pulmonary embolism, and
pericardial disease
LV size and function, RV size and function, valve func-
tion, aorta, pericardium
Syncope, palpitations, arrhythmia Structural heart disease leading to haemodynamic in-
stability and arrhythmia, including acquired and con-
genital heart disease
LV size, wall thickness and function, RV size and func-
tion, valve function, arterial and venous connections
Cardiac disease identified by
other investigation
Acute and chronic HF, acute coronary syndromes,
VHD, cardiomyopathy, pericardial effusion
LV size and function, RV size and function, valve
function
Infective endocarditis Supporting evidence of IE and/or complications thereof High resolution valve assessment and complications
Emboli and cardiac masses Mass consistent with thrombus, tumour, vegetations Characterization of mass, size, location and involve-
ment of adjacent structures
Patients at risk of CV disease Hypertension, genetic predisposition to cardiac disease,
exposure to cardiotoxic medications
LV size, wall thickness and function, including advanced
characterization of diastolic function and deform-
ation, RV size and function
Adult congenital heart disease Broad range of inherited conditions with de novo pres-
entation or previous surgery
Segmental analysis to define arterial and venous con-
nections, valve and ventricular morphology and func-
tion, intracardiac pressure and shunts
Prior to planned
non-cardiac surgery
Active cardiovascular symptoms or proven CV disease LV size, wall thickness and function, RV size and func-
tion, valve function
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those with confirmed or suspected PH, TTE may help to determine a
cause, in particular confirming or excluding the presence of left heart
disease and Doppler can distinguish pre- and post-capillary pulmon-
ary hypertension.
Chest pain
Ambulatory patients presenting with chest pain are common, al-
though only a small proportion will have an ACS. In the community,
the most common causes include chest wall pain (e.g. costochondri-
tis), and gastro-oesophageal reflux disease, with other considerations
including pulmonary aetiologies (pneumonia, pulmonary embolism)
and psychological disorders (anxiety, panic disorder). The first step is
to exclude ACS, usually based on clinical parameters, initial ECG and
biomarker measurement.
Acute coronary syndrome
In patients with non-ST segment elevation ACS, management de-
pends on information additional to history and clinical examination
which comprises: the response to anti-ischaemic treatment, bio-
marker measurement (high sensitivity troponin), repeat ECG or con-
tinuous ST-segment monitoring, ischaemic risk score assessment
(GRACE score) and TTE.38 TTE is useful not only as a diagnostic tool
but is important in risk stratification. The presence of LV systolic dys-
function has an independent prognostic role in predicting both short-
and long-term cardiac events.39,40
Chronic stable angina
Although overall LV function is often normal in patients with stable
angina, regional wall motion abnormalities may be identified that pro-
vide evidence in support of a diagnosis of CAD. In those with a con-
firmed diagnosis of chronic stable angina, TTE is useful to quantify
global LV function, which is an important prognostic parameter.41 In
addition to 2D, tissue Doppler and myocardial deformation imaging,
along with assessment of diastolic function are useful for detecting
early myocardial dysfunction in those with preserved LV ejection
fraction as an explanation for exercise-induced symptoms.42
Acute pericarditis
Acute pericarditis is an inflammatory syndrome with or without PEff.
TTE is recommended in all patients in whom the diagnosis is sus-
pected.16 The aim of TTE is to identify PEff and to exclude ventricular
dysfunction due to myocardial involvement. The presence of a large
PEff (>20 mm) is one of the major risk factors for poor prognosis.43
Valvular heart disease
The development of chest pain during exercise in a patient with se-
vere aortic stenosis in the absence of CAD is a clear indication for
intervention and TTE is mandated in any patient presenting in this
way who has a murmur or clinical evaluation consistent with this
diagnosis.27
Acute aortic syndromes
Although TTE may be used in the emergency room, particularly in
the assessment of the proximal ascending aorta, CT is the recom-
mended first line imaging modality for those with suspected aortic
syndromes in the non-emergent setting.20 In the stable patient, TTE
may complement CT by adding information on presence, severity
and mechanism of aortic regurgitation, PEff, and LV function.
Syncope, palpitations, and arrythmia
Syncope and palpitations are among the most common symptoms
leading to medical presentation and the role of TTE is to rule out
structural cardiac disease where there is a clinical suspicion on
examination or following a 12-lead ECG.44,45 A normal TTE in this
setting is an important finding that helps to direct the clinician in
diagnosis and management. It is uncommon for TTE to define a
sole cause for syncope or presyncope without the need for add-
itional tests in the absence of a clinical suspicion of structural ab-
normality, since the most commonly identified causes such as
aortic stenosis, HCM, DCM, ARVC, and pulmonary hypertension
are usually at an advanced stage. In the presence of impaired LV
function, other tests to evaluate a cardiac cause for syncope should
be performed.44 Diagnosis of the cause of palpitations is provided
by electrocardiographic recording of a rhythm disorder or the ab-
sence of it at the time of symptoms and TTE is not indicated unless
there is a clinical suspicion of structural heart disease on examin-
ation or following a 12-lead ECG. Likewise, in those patients with
confirmed multiple premature ventricular complexes and/or sus-
tained or non-sustained arrhythmias, including atrial fibrillation,
supraventricular tachycardia and ventricular tachycardia, TTE is
required for diagnosis of underlying structural CV disease, for risk
stratification and planning treatment.46,47
Cardiac disease suspected following
other investigation
Elevated troponin
Although cardiac troponin testing is integral to the diagnosis of chest
pain in the acute medical patient, elevation is not synonymous with
ACS. The value of TTE in patients with elevated troponin and sus-
pected ACS has been discussed but the role of TTE in the patient
with an alternative cause is more complex. All cardiac troponin eleva-
tions are important and may have prognostic significance. Firstly, in
patients with an acute elevation in troponin but no evidence of is-
chaemia, for example in severe sepsis, stroke, or other critical illness,
a dynamic change in biomarker is associated with high risk and TTE is
useful for measurement of LV function.48 Secondly, in patients with a
chronic elevation in troponin, for example HF and kidney disease,
while this is associated with adverse prognosis, the role of TTE in
management is not clear. Thirdly, measurement of troponin may be
used as a sensitive and specific marker of myocardial injury, for ex-
ample in patients receiving cancer therapy. In these patients, elevation
in biomarkers may be used to monitor the effects of chemotherapy,
with elevation then a stimulus to TTE.49 While change in ejection
fraction is the most common method of diagnosis of cancer therapy-
related cardiac dysfunction, global longitudinal strain is the optimal
parameter of deformation for monitoring of sub-clinical LV
dysfunction.50
Elevated natriuretic peptides
Since HF symptoms are non-specific, use of natriuretic peptides is
recommended for screening patients with acute onset, worsening or
gradual onset of symptoms.51 TTE is then required to confirm or
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refute the diagnosis, and then to assess aetiology if a cardiac cause is
identified, since natriuretic peptides may be elevated in non-primary
cardiac illnesses, including sepsis, severe anemia, stroke and pulmon-
ary disease.24
Radiological abnormality
Increased cardiothoracic ratio on a standard chest-X-ray is a com-
mon finding often disproved on TTE.52 Other findings on a CXR that
prompt referral to TTE include a large thoracic aorta, pleural effusion
or pulmonary congestion, while identification of a PEff on non-gated
computed tomography may necessitate assessment to exclude im-
pending tamponade.
Infective endocarditis (IE)
The diverse nature of IE and evolving epidemiology ensures that this
condition remains a challenge. In addition to microbiological investi-
gation, TTE is the technique of choice for diagnosis in those with
fever of unknown origin and should be performed as soon as IE is sus-
pected. In those with a confirmed diagnosis, TTE also plays a central
role in planning management and monitoring outcome. TTE is rec-
ommended as first-line, with TEE indicated in those with a negative
TTE but high clinical suspicion and as first-line in those with a pros-
thetic valve or intracardiac device. TEE is also considered useful fol-
lowing positive TTE.53 Echocardiography of all patients with
Staphylococcus aureus bacteraemia is recommended due to the high
but unexpected prevalence of IE.54
Emboli
TTE is the first-line imaging modality of choice in those with poten-
tial cardiac source of embolism.55 In these patients, there is likely
to be an incremental advantage over and above the use of standard
TTE with the addition of 3D, contrast and TEE. The type of echo-
cardiography used depends on the clinical presentation. In patients
with atrial arrhythmia, structures away from the chest wall, in par-
ticular the posterior aspect of the left atrium, left atrial appendage
and descending thoracic aorta, are best imaged using TEE due to
improved resolution. In patients with a recent history of ACS, par-
ticularly those with anterior MI, large infarct size, severe apical wall
motion abnormality or LV aneurysm, TTE is the preferred tech-
nique but with the additional option of transpulmonary contrast to
improve sensitivity in cases with suboptimal image quality.56 In pa-
tients with cryptogenic stroke, TTE with agitated saline contrast
and provocative manoeuvres including Valsalva is useful to detect
patent foramen ovale and small ASDs, although controversy re-
mains as to the role of closure and in which patients this imaging
should be performed.57,58
Cardiac masses
TTE is the primary imaging modality for assessment of intracardiac
masses, determining size, location and involvement of adjacent struc-
tures, as well as contrast techniques to distinguish thrombus from
tumour.59
Echocardiography in the non-emergent,
first assessment of the patient at risk of
cardiac disease
Hypertension
The aims of TTE include the diagnosis of LV hypertrophy, assessment
of LV geometry and measurement of diastolic function, including left
atrial size.60 Although TTE is more sensitive than ECG in diagnosing
LVH and abnormalities detected by echocardiography have add-
itional predictive power, there are no convincing data that TTE im-
proves CV risk classification.61 Evidence of LVH is one of the
indicators of asymptomatic end-organ damage used to calculate total
CV risk and may be used to direct therapy, as can carotid-intima med-
ial thickness.
Diabetes mellitus
Successful risk management of DM depends upon accurate detection
and intensive management of identifiable, modifiable risk factors, and
clinical risk scores are the main method to identify those at low, me-
dium and high risk. Although coronary artery disease and heart failure
however, are common, screening with TTE is not recommended in
asymptomatic patients with DM unless the ECG is abnormal.62
Dyslipidaemias
Although intervention for dyslipidaemias is directed by estimation of
total CV risk, including presence or absence of hypertension, TTE
does not play a role in risk profiling or targeting treatment in these
patients.63
Asymptomatic adults
Routine screening with echocardiography and other imaging modal-
ities is not recommended to predict CV events There is no evidence
that screening for CV disease in asymptomatic adults with TTE–using
stress or not–adds incremental value to the use of clinical risk algo-
rithms.64 Screening of asymptomatic adults >65 years for abdominal
aortic aneurysms may be the exception and is recommended due to
the grim prognosis of rupture compared to the excellent results of
repair.65
Genetic predisposition and screening
The diagnosis of CV disease in asymptomatic patients and their rela-
tives with known or suspected genetic predisposition to CV disease,
for example Marfan syndrome, bicuspid AV, HCM, ARVC, relies
upon a combination of history, clinical examination, genetic testing
and imaging. While there are advantages and disadvantages to each
imaging modality in specific cases and aetiologies, TTE is recom-
mended in the initial evaluation of such patients and their family mem-
bers due to the ability to define ventricular morphology and function,
valvular abnormalities, and associated proximal aortopathy.66
Cardiotoxic therapy
Chemotherapy and radiotherapy are known to have multiple poten-
tial adverse effects on CV structure and function, although the timing
of these effects vary dependent upon susceptibility of the patient and
the treatment regime used. TTE is the cornerstone in the cardiac
imaging evaluation of patients in preparation for, during, and after
cancer therapy, because of its wide availability, easy repeatability,
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versatility, lack of radiation exposure, and safety in patients with con-
comitant renal disease.49 Recommended protocols using TTE en-
compass not only 2D assessment of structure and function but
recommend the routine use of 3D and also deformation analysis for
reproducible quantification of volumes and function, as well as stand-
ard assessment of strain, diastolic function, valvular abnormalities,
and pericardial consequences of chemotherapy and radiotherapy.50
Adult congenital heart disease (ACHD)
ACHD encompasses a broad range of patients, from de novo presen-
tations in adulthood to the assessment of patient with previous pallia-
tive repair and its consequences. Survival to adulthood is increasing,
although varies with severity of disease, from 98% of those with mild
disease to 56% of those with severe forms of ACHD.67 With increas-
ing life expectancy, there is the additional interaction between
acquired disease and the consequences of ACHD, either precipitat-
ing symptoms in hitherto stable disease or onset of consequences
from undiagnosed disease. TTE represents the first-line investigation
for diagnosis and follow-up of ACHD, since a segmental approach
will help to define arterial and venous connections, valve and ven-
tricular morphology and function, and estimate intracardiac pressure
and shunts.68 While TTE is first-line, it is recognized that it is user de-
pendent and requires special expertise in ACHD populations.
Assessment of the patient prior to
planned non-cardiac surgery
The risk of CV complications during non-cardiac surgery depends
upon the condition of the patient before surgery, the severity of his
or her co-existing morbidity, and the magnitude, type and duration of
surgery proposed. Alongside the risk attributable to specific types of
surgery, the functional capacity of the patient is the most important
patient-related factor to determine likelihood of peri-operative car-
diac events.25 Although TTE can identify patients at higher risk, its use
should be reserved for those patients in whom the result would influ-
ence or change management and routine use is not recommended.
For example, TTE is not recommended in those patients with stable
heart disease undergoing low and intermediate-risk surgery but in
symptomatic, unstable patients undergoing high risk surgery, careful
evaluation of the patient by a team of integrated multidisciplinary spe-
cialists may be informed by TTE.
Repeat echocardiography
following first study
This section relates to the second or repeated use of TTE in an in-
patient or out-patient setting (Table 3). The echocardiographic exam-
ination will in most cases be a complete study acquiring a compre-
hensive set of images and measurements.69 In the majority of cases,
TTE will be performed in patients with CV disease confirmed on pre-
vious assessment.
Heart failure
HF is a dynamic syndrome characterized by gradual deterioration
and episodic, acute exacerbations. TTE is the imaging modality of
choice for follow-up of HF to determine progression or response to
treatment, focussing on ventricular volumes, function, associated
valve disease and PH.5 TTE is used to investigate symptoms, acute or
chronic deterioration and to determine prognosis, the latter being
important to inform decisions on treatment with devices or trans-
plantation, and patient counselling with respect to end-of-life.
Estimating prognosis takes into account age, aetiology, NYHA class
and co-morbidities including renal failure, anaemia and hyperuricae-
mia, while integrating imaging variables such as ejection fraction, wall
thickness, geometry and filling pattern.70 The routine repeat assess-
ment of ventricular function however, in the absence of changing clin-
ical status or a change in treatment, is not warranted.
Indications for device therapy
TTE has a central role in selection of patients with symptomatic HF
who may benefit from an implantable cardioverter-defibrillator for
prevention of sudden cardiac death, based on LV ejection fraction
(LVEF < 35%).47 Although the decision to implant a cardiac
resynchronization device is based primarily on QRS duration > 150
ms, TTE is used to quantify LVEF < 35% and thereby acts as a gate-
keeper for appropriate device implantation. TTE may also identify pa-
tients with secondary mitral regurgitation who would benefit from
implantation.71 The role of TTE in those with borderline QRS dur-
ation 120–150 ms continues to be a source of debate.72 TTE is not
recommended for routine optimization of all resynchronization
devices.
TTE is also acts as a gate-keeper to select suitable candidates with
end-stage heart failure for mechanical circulatory support, based on
both LVEF <25% and on identification of right ventricular dysfunction.
Repeat TTE in patients with mechanical circulatory support is useful,
not only to optimize function and trouble-shoot complications but
also to monitor response, with a view either to removal of the assist
device (bridge to recovery) or to listing for transplantation (bridge to
candidacy).51 TTE may be indicated early post-implantation when
PEff and tamponade are suspected, and whenever there is a suspicion
of device-related infection.
Cardiactransplantation
The International Society for Heart and Lung Transplantation recom-
mends the use of TTE for pre-operative assessment of the donor and
recipient. TTE measurement of ventricular function is a component
of the Heart Failure Survival Score, which identifies cut-points for
transplant listing.73 While TTE is used in the early post-transplant
phase to monitor right ventricular function and tricuspid regurgita-
tion, longer term routine TTE to monitor rejection is not considered
useful as an alternative to endomyocardial biopsy.74 TTE is com-
monly used however, when there is a clinical suspicion of acute allo-
graft rejection and a baseline TTE is performed at least 6 months
from the transplantation and then following endomyocardial biopsies,
usually every 6 months.75
Ischaemic heart disease
There is no indication for use of TTE on a regular basis in patients
with stable CAD in the absence of a change in clinical status. Sudden
deterioration with recurrence of chest pain or other evidence of clin-
ical compromise should trigger re-evaluation, specifically searching
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for evidence of progressive LV dysfunction or mechanical
complications.17
Valvular heart disease
Asymptomatic patients with VHD need to be regularly re-assessed
for change in ventricular size and function, as well as estimation of the
likelihood of PH regardless of symptoms. The frequency of a repeat
TTE is based on the type and severity of the valve lesion, the sus-
pected rate of progression, and the haemodynamic consequences of
the valve lesion.
Aortic regurgitation
A decrease in LVEF <_ 50% or enlargement of the LV internal dimen-
sion (LVEDD >70 mm; LVESD >50 mm) in asymptomatic patients
with severe AR determines poor survival after aortic valve replace-
ment, demanding regular TTE. Serial follow-up is recommended 6-
months after first assessment and then at yearly intervals if stable for
severe AR, and every 2 years in patients with mild or moderate
AR.27,76
Aortic stenosis
AS is progressive but there is marked individual variability.
Assessment of asymptomatic severe AS is recommended every 6
months with TTE to detect LVEF <50%, velocity >5.5 m/s or progres-
sion in peak velocity >0.3 m/s/year. In those with mild or moderate
AS, re-evaluation is recommended yearly but with intervals extended
to 2–3 years in those without significant calcification.27
Bicuspid aortopathy and valve disease (BAV)
Patients with BAV can experience a more rapid progression of valve
degeneration and also are at increased risk of thoracic aortic disease.
In those with a normal aortic root, annual TTE may be adequate but
in those with an increase in aortic dimensions > 3 mm/year or >45
mm, regular measurement with another imaging modality specifically
for the aorta is indicated.65
Mitral stenosis (MS)
MS is a progressive disease and serial follow-up with TTE is indicated
to identify MV area < 1.5 cm2 (by 3D where feasible) and PH (resting
PASP > 50 mmHg) that are indicators for intervention. TTE may also
guide introduction of anti-coagulation in sinus rhythm when there is
spontaneous contrast or LA dilatation >50 mm. Annual TTE should
be performed in asymptomatic severe MS but at 2–3 years in those
with a MV area >_ 1.5 cm2.27
Mitral regurgitation (MR)
TTE is essential to monitor increase in LV size (LVESD >45 mm), fall in
LVEF <60%, PH (PASP >50 mmHg) and LA size (volume >60 mL/m2)
on an annual basis in asymptomatic severe MR. Asymptomatic pa-
tients with moderate MR and preserved LV function can be followed
up with TTE every 2 years, and every 3 to 5 years in those with mild
MR.27,76
Tricuspid valve (TV) disease
Patients with severe TV disease should be re-assessed on an annual
basis, although CMR or 3D echocardiography should ideally be used
....................................................................................................................................................................................................................
Table 3 Clinical scenarios for repeat echocardiography following a first study
Scenario Potential scenarios for repeat TTE Focus of assessment
Heart failure Change in HF status, prognosis, therapeutic decisions,
including selection for device therapy, pharmacother-
apy and transplant
LV size and function, RV size and function
Valvular heart disease Progression of VHD, prosthetic valve assessment, preg-
nancy in context of VHD
Valve assessment, haemodynamic consequences,
including LV size and function, RV size and function.
Infective endocarditis Repeat following negative study with high clinical suspi-
cion, change in clinical status in proven IE
Valve assessment, haemodynamic consequences includ-
ing LV size and function, RV size and function, aorta,
pericardium
Cardiomyopathy Inherited and reversible cardiomyopathies. LV size and function, RV size and function, response to
treatment, complications specific to conditions
Pericardial disease Pericardial effusion (change in clinical condition, re-
sponse to intervention), pericardial constriction and
predisposition
Pericardium and haemodynamic consequences of
compromise
Patients at risk of CV disease Genetic predisposition to cardiac disease, exposure to
cardiotoxic medications (follow-up)
LV size, wall thickness and function, including advanced
characterization of diastolic function and deform-
ation, RV size and function
Adult congenital heart disease Broad range of inherited conditions with de novo pres-
entation or previous surgery
Valve and ventricular morphology and function, intra-
cardiac pressure
Following device therapy Early following pacing, resynchronization and cardio-de-
fibrillator therapy, percutaneous valve interventions,
appendage occlusions, complex percutaneous coron-
ary intervention
LV size and function, RV size and function, valve func-
tion, pericardium
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for surveillance of RV size and function.27,76 In those with persistent
or recurrent TR following left-sided valve surgery, regular re-
assessment is warranted dependent on severity, ventricular size and
function, and likelihood of right heart surgery.
Prosthetic valves
An initial TTE performed within 4–6 weeks of valve implantation is
recommended in all patients after surgery or percutaneous interven-
tion to serve as a baseline for future comparisons.77 In patients with
mechanical valve prostheses, routine annual echocardiographic
evaluation is not necessary if the postoperative baseline study is nor-
mal and there is no change in clinical status. Routine, annual TTE is
recommended however in bioprosthetic valves 5 years after implant-
ation due to the risk of degeneration. Earlier evaluation may be pru-
dent in selected patients at increased risk of early bioprosthetic valve
degeneration, including those with renal impairment, diabetes melli-
tus, abnormal calcium metabolism, systemic inflammatory disease,
and in patients <60 years of age. Onset of HF, systemic thrombo-
embolism, haemolysis, or a new murmur on auscultation should raise
the suspicion of prosthetic valve dysfunction and necessitates TTE
examination.27 Asymptomatic patients with prosthetic valve regurgi-
tation or stenosis need more frequent follow-up for evidence of pro-
gressive LV dilatation and systolic dysfunction with the same criteria
for timing of surgical intervention as those for native valve regurgita-
tion. TTE is less sensitive than TEE for the evaluation of the cause of
prosthetic valve dysfunction.
Pregnancy during follow-up of VHD
Pre-pregnancy evaluation of valve function, ventricular size and func-
tion, and pulmonary pressures is warranted in women with known
VHD. In those who are pregnant, stenotic lesions carry a higher preg-
nancy risk than regurgitant lesions, with left-sided VHD a higher com-
plication rate than right-sided lesions. Monthly TTE is therefore
recommended in left-sided stenosis, while frequency should be
individualized in those patients with regurgitation.78 In those who are
pregnant with mechanical prostheses, monthly TTE is recommended,
with additional imaging performed in a patient with any type of pros-
thesis if breathless or with evidence of emboli.
Infective endocarditis
Repeat TTE within 7–10 days is recommended in cases of initially
negative examination when clinical suspicion of IE remains high, par-
ticularly in the presence of prosthetic material. Repeat TTE is manda-
tory in patients with IE who have worsening or persisting symptoms,
and in patients at high risk of complications including HF, valve failure,
peri-valvular extension, and embolism.79 In such patients, the aim of
TTE is to identify a subgroup of patients who may benefit from early
surgery.80 In stable patients with IE, the benefit of routine repeat TTE
is not proven. There is no evidence of benefit from routine repeat
TTE after completion of antibiotic therapy but TTE is recommended
at discharge as a baseline for future comparisons in case of suspected
recurrent IE, particularly in those who have undergone surgery.
Cardiomyopathy
HCM
There is a life-long process of progressive, adverse cardiac remodel-
ling in HCM including change in systolic and diastolic function, wall
thickness, cavity size, and outflow tract gradient.30 The variability of
the disease means that annual or bi-annual TTE should be considered
to monitor potential changes in morphology and function as well as
in risk profile.81 Repeat TTE is warranted when there is also a change
in clinical status. Repeat TTE has a role in the assessment of response
to medical, percutaneous and interventional treatment of HCM, par-
ticularly in the management of LV outflow tract obstruction.66
DCM, ARVC, RCM
Although these are progressive diseases, there are no data on which
to base a recommendation for routine surveillance with TTE in stable
patients without a change in clinical status. Principles that are valid for
HF patients are to be followed until new evidence is available for
these patients, although it is common practice to perform annual
TTE. LVNC should be present from birth but other conditions can
mimic LVNC and these may progress over time. Furthermore, in
those with known LVNC it is common practice to perform annual
TTE to follow onset and progression of heart failure.
Reversible cardiomyopathies
Peripartum CM, tachycardia-induced CM and Tako-tsubo CM are
potentially reversible, often within 6 months. TTE is helpful to moni-
tor response to treatment and to detect complications, including RV
involvement, thrombus formation, and MR. While no firm data exist
for timing follow-up TTE, there is support for imaging at 3 and/or 6
months depending on local availability and patient clinical status.82
Pericardial disease
Acute pericarditis
A first episode of acute pericarditis is expected to subside with ap-
propriate treatment within 7 days and while TTE should be per-
formed once in suspected cases, repeat study is not needed unless
there are complications, including a moderate or large effusion, tam-
ponade, failure to respond to therapy, or persisting fever and chest
pain >1 week.16 Restriction of exercise should be considered for
those with acute pericarditis until resolution of symptoms, ECG and
TTE abnormalities if present.
Recurrent pericarditis
This usually occurs within 1–3 months of the initial episode but PEff is
less common than in the acute phase and there is no consensus on
the optimal frequency of repeat TTE.
Pericardial effusion (PEff)
TTE is the primary imaging modality for surveillance of PEff. Repeat
TTE is useful to guide drainage, determining duration of an indwelling
drain, and to monitor recurrence. Frequency of repeat TTE should
be guided by clinical status. In asymptomatic individuals with chronic
PEff, there are no data to indicate how often an echocardiogram
should be repeated.83 Auto-reactive pericarditis and asymptomatic
PEff are common in systemic autoimmune diseases, including
rheumatoid arthritis and systemic lupus erythematosus, yet the
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frequency with which screening TTE should be performed is not
clear in the absence of clinical concern.
Pericardial constriction (PC)
Suspicion is raised in patients with signs of predominantly right-sided
heart failure although in the majority PC is a chronic condition that is
often diagnosed late. TTE is recommended 5 years after exposure in
those who are at high risk for radiotherapy-induced heart disease and
10 years after exposure in others.84 Repeat TTE is recommended in
patients following pericardiocentesis, medical treatment or pericar-
diotomy in effusive-constrictive pericarditis and transient PC.83
Aortic disease
While TTE is useful for evaluating the aortic root and proximal as-
cending aorta, CT or MRI are preferred for routine surveillance of
thoracic aortic dimensions.20 CT or MRI are also recommended for
routine surveillance following aortic dissection, intramural haemor-
rhage and penetrating aortic ulcer. TTE can be used for routine
follow-up in Marfan syndrome and BAV-associated aortopathy but
only when dilatation is restricted to the root and proximal ascending
aorta, and when concordance between the dimensions measured by
TTE and CT or MRI has been documented.20
Repeat echocardiography in the
assessment of the patient at risk of
cardiac disease
Hypertension
Repeat TTE to monitor for onset of CV complications of hyperten-
sion in the absence of symptoms or signs is not recommended and
there is no role in evaluating response to treatment.60 Conversely,
repeat TTE should be performed if there is a change in clinical status
or with poor control of blood pressure.85
Risk factors and asymptomatic adults
There is no incremental benefit to history and clinical risk estimation
in repeat TTE in asymptomatic individuals with or without DM, dysli-
pidaemias or other risk factors for CAD.
Genetic predisposition and screening
In first-degree relatives of patients with HCM in whom genetic status
is unknown, clinical assessment with ECG and TTE should be con-
sidered every 1–2 years between 10 and 20 years of age, and every 5
years thereafter (12 monthly if non-diagnostic abnormalities are pre-
sent) as late-onset hypertrophy can occur.86 First-degree relatives
who do not share the same disease-causing mutation as the proband
should be discharged from further follow-up.
First-degree relatives of patients with other CM including ARVC,
DCM, and RCM not known to be affected should undergo periodic
TTE in those cases where genetic testing is not categorical and where
late occurrence may arises. Screening every 5 years may be reason-
able. LVNC should be present from birth and no late occurrence is
to be expected.
Cardiotoxic therapy
Evaluation by TTE of ventricular size and function is recommended
before, during, and after cancer therapy. 3DE is the preferred
technique for monitoring LV function, although 2D TTE measure-
ment of global longitudinal strain is recognized as a more sensitive
means of detecting subclinical LV dysfunction during follow-up stud-
ies.49 For low dose type I toxicity, for example doxorubicin, repeat
TTE is recommended at the completion of therapy and 6 months
later. For patients exposed to type II toxicity, for example trastuzu-
mab, repeat TTE is recommended every 3 months during therapy
and at 6 months following completition of therapy.
Adult congenital heart disease
TTE is the primary imaging tool in the on-going management of the
adult with congenital heart disease. It is used to measure and follow-
up valve and ventricular function, ventricular mass, calculate pulmon-
ary pressure, and monitor intracardiac shunts. Special competency in
ACHD is important in TTE in this group of patients, particularly as
imaging becomes complicated by the super-imposition of acquired
disease with age. Frequency of repeat TTE should be decided on the
basis of type of congenital abnormality, type and result of surgical cor-
rection, the individual’s clinical condition and prognosis, and the avail-
ability of local medical services.67,68 In general, annual TTE should be
performed in any asymptomatic, clinically stable patient following in-
complete or palliative repair, for example Tetralogy of Fallot. In any
asymptomatic patient following complete repair without residual
structural or haemodynamic abnormality, there is no clear evidence
of benefit from regular repeat TTE. TTE should be performed in any
patient with documented ACHD to investigate a change in clinical
status or examination and to guide therapy.
Following device therapy and
intervention
There is increasing demand for TTE not only in the identification of
patients suitable for device therapy and intervention but for following
such patients after therapy. While it is common practice to monitor
implantation or exclude immediate and early complications, there
are very limited data however that demonstrate improved patient
care directly as a result of regular, repeat echocardiography following
device therapy and intervention.
Pacing, resynchronization, and cardio-defibrillator
therapy
The majority of complications from implantation of pacemakers,
resynchronization devices and cardio-defibrillators occur in-hospital
or within the first 6-weeks.87 TTE should be performed in all patients
soon following implantation to exclude mechanical complications,
including PEff, and to check on lead placement. There is no evidence
to support further echocardiography unless there is clinical concern
regarding complications such as device-related infection.
Transcatheter valve and device therapy
Early assessment with echocardiography within 24 hrs following
transcatheter valve intervention is recommended, whether or not
peri-procedural echocardiography is performed during the proced-
ure itself. The aim is to confirm function of the valve, exclude compli-
cations including paravalvar regurgitation and pericardial effusion, and
to act as a baseline for future comparison not only of the new device
but also of ventricular and other valve function.88 Thereafter, for
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transcatheter aortic valve implantation, follow-up evaluation is rec-
ommended as for surgically-implanted bioprostheses but additional,
repeat assessment of transcatheter mitral valve intervention is rec-
ommended at 6 months specifically to assess reverse ventricular
remodelling.88
For transcatheter repair of paravalvar regurgitation, peri-
procedural echocardiography is required but early assessment by
TTE within 24 hrs should also be performed to exclude complica-
tions and as a baseline for future reference. Additional repeat echo-
cardiography thereafter may be performed as planned for the
prosthetic valve itself with no additional imaging required without a
clinical suspicion of complications.
Following transcatheter or device occlusion of the left atrial ap-
pendage, follow-up echocardiography is performed within the first
month, at 6 months and then annually to ensure device stability, ab-
sence of leak and to exclude associated complications.89
Revascularization for IHD
There is no evidence to support routine TTE following percutaneous
revascularization.90 The rationale for and timing of echocardiography
in patients with stable angina and ACS has been discussed but repeat
imaging following percutaneous revascularization is not necessary un-
less the patient has had a complicated course, for example suspected
peri-procedural myocardial infarction, dissection or guidewire per-
foration. TTE should be performed as baseline prior to discharge fol-
lowing surgical revascularization.
Conclusions
Indications for TTE in the adult continue to grow and activity in many
departments across Europe increases inexorably. TTE is operator de-
pendent and it is vital that the test is performed by qualified individ-
uals within proficient departments that monitor quality.91,92 Demand
for TTE and the costs that arise from providing high quality imaging
necessitates that there is a clear incremental benefit to the patient
and the healthcare system from the performance of the test beyond
history and examination, taking into account other imaging modal-
ities. The degree of benefit will be subject to change and indications
will need to be subject to regular review.
Conflict of interest: None declared.
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